Highest-materiality recent filing
Neurocrine annual meeting re-elects three directors, approves equity plan and auditor
Re-elected Class III directors Kevin C. Gorman, Gary A. Lyons, and Johanna Mercier with over 76M votes each.
Neurocrine completes $2.9B acquisition of Soleno Therapeutics, adds VYKAT XR for Prader-Willi
Tender offer accepted 46.4M shares (88.9% of Soleno) at $53/sh cash; total equity value ~$2.9B.
Net product sales of $811.0M in Q1 2026, a 44% increase year-over-year, led by INGREZZA ($656.9M) and CRENESSITY ($153.3M).
Neurocrine to acquire Soleno Therapeutics for $53.00 per share in cash
Tender offer for all Soleno shares at $53.00 cash each; no financing condition.
Neurocrine reports Q4 2025 revenue $805.5M, EPS $1.48 GAAP; guides INGREZZA 2026 sales $2.7-2.8B
Q4 total net product sales $798.3M (+29% YoY); full year $2.83B (+22% YoY).
Neurocrine extends former CMO Eiry Roberts as Strategic Advisor through Dec 31, 2026
Roberts, former CMO, transitioned to Strategic Advisor effective June 2, 2025; term extended to Dec 31, 2026 (Amended Employment Agreement).
Neurocrine Q3 net product sales $790M (+28% YoY); INGREZZA $687M (+12%); CRENESSITY $98M
GAAP EPS $2.04 (diluted) vs $1.24 YoY; Non-GAAP EPS $2.17 vs $1.81; net income $209.5M.
Neurocrine Biosciences Q2 2025: Revenue $687.5M up 16.5% YoY; valbenazine Phase 3 schizophrenia miss
Total revenue $687.5M; INGREZZA $624.4M (+8% YoY), CRENESSITY $53.2M (launch year).
Neurocrine CMO Eiry Roberts to step down; Sanjay Keswani named successor June 2, 2025
Dr. Eiry Roberts transitions from CMO to Strategic Advisor to the CEO, effective June 2, 2025 through Dec 31, 2025.
Neurocrine holds 2025 annual meeting; shareholders approve new equity plan and amended ESPP
Four Class II directors elected for three-year terms expiring 2028: Kyle Gano, Richard Pops, Shalini Sharp, Stephen Sherwin (each >72M votes).
Neurocrine Q1: INGREZZA $545M (+8%), CRENESSITY $14.5M; GAAP EPS $0.08; reaffirms FY25 guide
INGREZZA net product sales $545M in Q1 2025, up 8% YoY; CRENESSITY sales $14.5M with 413 patient enrollment forms.
Neurocrine appoints Sanjay Keswani as CMO effective June 2; Roberts transitions to advisory role
Sanjay Keswani appointed CMO effective June 2, 2025; Eiry Roberts transitions to strategic advisory role after 7 years as CMO.
Neurocrine reports Q4 INGREZZA sales $615M (+23% YoY); 2025 guidance $2.5-2.6B
INGREZZA net product sales $2.3B for FY2024, up 26% YoY; Q4 sales $615M (+23% YoY).
Neurocrine restructures Takeda deal for osavampator; gets global rights ex-Japan
Neurocrine obtains exclusive worldwide development/commercialisation rights for osavampator except Japan, converts from profit-sharing to royalty-bearing license.
Neurocrine Biosciences launches CRENESSITY for classic CAH at WAC ~$38,333/month
CRENESSITY commercially available in U.S. for classic CAH (ages 4+); dispensed exclusively via PANTHERx Rare specialty pharmacy.
Neurocrine Biosciences launches $300M accelerated share repurchase with Goldman Sachs
Entered into ASR agreement with Goldman Sachs & Co. to repurchase $300M of common stock.
Neurocrine Q3 INGREZZA sales $613M (+26% YoY); raises FY2024 guidance; $300M buyback
INGREZZA net product sales $613M in Q3 2024, up 26% YoY; raised 2024 sales guidance to $2.30-$2.32B.
Neurocrine appoints Kyle Gano as CEO effective Oct 11, 2024; base salary $900k
Kyle Gano, Ph.D. named President and CEO effective October 11, 2024, under an amended employment agreement.
Neurocrine's NBI-1117568 meets Phase 2 primary endpoint; 7.5-point PANSS reduction vs placebo
20 mg once-daily dose met primary endpoint: placebo-adjusted PANSS reduction of 7.5 points (p=0.011, effect size 0.61) at Week 6.
Neurocrine Q2 INGREZZA sales $580M (+32% YoY); raises FY guidance; CEO Gorman to retire Oct 11
INGREZZA Q2 net product sales $580M (+32% YoY); FY 2024 guidance raised to $2.25-$2.3B.
Neurocrine CEO Kevin Gorman to retire Oct 11; Kyle Gano appointed successor
Kevin C. Gorman, Ph.D. to retire as President and CEO effective October 11, 2024; will remain on the board.
Neurocrine stockholders elect directors, approve say-on-pay, amended equity plan, ratify EY
All four Class I directors elected: Rastetter, Morrow, Norwalk, Poon; each received >72M votes.
Neurocrine Q1: INGREZZA sales $506M (+23% YoY); GAAP EPS $0.42, non-GAAP EPS $1.20
INGREZZA net product sales $506M in Q1 2024 vs $411M in Q1 2023, up 23% year-over-year.
Neurocrine Q4 INGREZZA sales $500M (+25% YoY); FY 2024 guidance $2.1-$2.2B
Q4 GAAP net income $147.7M ($1.44 diluted EPS) vs $89M ($0.88) in Q4 2022; non-GAAP EPS $1.54.
Neurocrine settles all INGREZZA patent litigations; generic entry starts March 1, 2038
Resolved patent litigation with Zydus; Zydus can sell generic INGREZZA from Oct 1, 2038 (or earlier under certain circumstances).
Neurocrine settles Lupin patent litigation; generic INGREZZA entry set for March 1, 2038
Settled with Lupin Limited and Lupin Pharmaceuticals; Lupin may sell generic INGREZZA starting March 1, 2038, or earlier under certain circumstances.
Neurocrine Q3 INGREZZA sales $486M (+29% YoY); raises 2023 guidance to $1.82-1.84B
INGREZZA Q3 net sales $486M (+29% YoY); total product sales $492M.
Neurocrine settles INGREZZA patent litigation; generic entry delayed to 2040
Settlement with Sandoz and Crystal grants generic INGREZZA license starting Feb 1, 2040, or earlier under certain conditions.
Neurocrine's crinecerfont Phase 3 pediatric CAH study meets primary, key secondary endpoints
Primary endpoint: statistically significant decrease in serum androstenedione at Week 4 vs placebo (p=0.0002).
Neurocrine's crinecerfont meets Phase 3 endpoint in CAH adults; FDA submission planned for 2024
Phase 3 CAHtalyst Adult study met primary endpoint: significant % reduction in daily glucocorticoid dose with androgen control (p<0.0001).
Neurocrine Q2 beats with INGREZZA $440M (+26% YoY); raises 2023 sales forecast to $1.77-1.82B
Q2 total revenue $452.7M vs $378.2M YoY; GAAP EPS $0.95 vs loss of $0.18, non-GAAP EPS $1.25 vs $0.84.
Neurocrine CMO Eiry Roberts to retire in 2025; search underway
Chief Medical Officer Eiry W. Roberts, M.D., notified Neurocrine of her plan to retire in 2025 for personal reasons.
Neurocrine appoints Christine Poon to board; bylaws amended to increase board to 10
Christine A. Poon appointed as Class I director effective July 11, 2023, term until 2024 annual meeting.
Neurocrine shareholders approve amended 2020 equity plan and elect directors at 2023 annual meeting
Stockholders approved amendment to 2020 Equity Incentive Plan with 84.95% of votes cast in favor.
Neurocrine Q1 GAAP net loss $76.6M; INGREZZA sales $410M (+36% YoY)
INGREZZA net sales $410M, up 36% YoY; guidance reiterated at $1.67-1.77B for FY2023.
Neurocrine settles INGREZZA patent litigation with Teva; generic entry allowed Feb 2040
Settlement grants Teva right to sell generic INGREZZA in the U.S. starting February 1, 2040, or earlier under certain conditions.
Neurocrine closes collaboration with Voyager; pays $136M upfront, buys $39M in stock
Collaboration Agreement with Voyager became effective Feb 21, 2023 after HSR waiting period expired.
Neurocrine Biosciences adopts proxy access bylaw and updates stockholder nomination procedures
Proxy access: stockholder(s) holding 3%+ for 3+ years can nominate up to 2 or 20% of directors.
Neurocrine Q4 INGREZZA sales $399M; guides FY23 INGREZZA $1.67-1.77B
Q4 2022 INGREZZA net product sales $399M (+33% YoY); full year $1.43B.
Neurocrine and Voyager form $175M upfront gene therapy collaboration for GBA1 and rare CNS targets
$175M upfront: ~$136M cash to Voyager plus $39M equity at $8.88/share (50% premium to 30-day VWAP).
Neurocrine Q3 2022: INGREZZA sales $376M, GAAP EPS $0.69; raises FY guidance
Q3 INGREZZA net product sales $376M (+31% YoY); TRx ~68,600 (+32% YoY).
Neurocrine to acquire Diurnal Group for £48.3M cash
Acquiring entire issued share capital of Diurnal for ~£48.3M (~$56.5M) in an all-cash transaction.
GAAP net loss $16.9M ($0.18 loss per diluted share) vs net income $42.3M in Q2 2021, largely due to $70M debt extinguishment loss.
Neurocrine repurchases $31.4M of 2.25% Convertible Notes due 2024 for $41.5M
Repurchased ~$31.4M principal of 2024 Convertible Notes for ~$41.5M including accrued interest.
Neurocrine Biosciences repurchases $179.4M of convertible notes, reduces debt by ~60% over two years
Repurchased $179.4M principal of 2.25% Convertible Senior Notes due 2024 for ~$224M cash plus stock-price-based component and accrued interest.
Neurocrine shareholders approve equity plan amendments, elect directors at 2022 annual meeting
Three Class II directors elected: Richard Pops, Shalini Sharp, Stephen Sherwin; each received >72M votes.
Neurocrine Q1: INGREZZA sales $303M (+32% YoY), GAAP EPS $0.14, reaffirms FY guidance
Net product sales $303M (+32% YoY); total revenue $310.6M incl $5.6M collaboration revenue.
Neurocrine reports 2021 INGREZZA sales of $1.1B, guides 2022 sales $1.25-1.35B
Total revenue FY 2021 $1.13B (+8% YoY); INGREZZA net sales $1.09B (+10% YoY).
Neurocrine Biosciences reports preliminary Q4 2021 INGREZZA sales ~$301M, FY ~$1.1B
Q4 INGREZZA net sales ~$301M ($296M inventory-adjusted), up 25% YoY; prescriptions up 32% YoY.
Neurocrine Biosciences' license with Heptares effective; $100M upfront due
Collaboration and License Agreement with Heptares Therapeutics becomes effective Dec 22, 2021 after HSR clearance.
Sanjay Keswani, M.D. will succeed Eiry W. Roberts, M.D. as the Chief Medical Officer of the Company, effective June 2, 2025.
Sanjay Keswani, M.D. will succeed Eiry W. Roberts, M.D. as the Chief Medical Officer of the Company, effective June 2, 2025.
Dr. Keswani will succeed Dr. Roberts, who has served as Chief Medical Officer for the past seven years, and who agreed to remain with the Company in a strategic advisory role following her succession by Dr. Keswani.
On April 2, 2025, Sanjay Keswani, M.D. agreed to succeed Eiry W. Roberts, M.D. as the Chief Medical Officer of Neurocrine Biosciences, Inc. (“Neurocrine Biosciences” or the “Company”), effective June 2, 2025.
Pursuant to the Employment Agreement, Dr. Gano will serve as Neurocrine Biosciences’ President and Chief Executive Officer effective October 11, 2024 (the “Effective Date”).
Kevin C. Gorman, Ph.D. will retire as Neurocrine’s President and Chief Executive Officer effective as of October 11, 2024 (the “Transition Date”).
effective as of the Transition Date, Dr. Gano has been appointed to the Board as a Class II director to serve until Neurocrine’s 2025 annual meeting of stockholders.
appointment of Kyle Gano, Ph.D., age 51, to serve as Neurocrine’s President and Chief Executive Officer, effective as of the Transition Date.
On July 10, 2023, Eiry W. Roberts, M.D., notified Neurocrine Biosciences, Inc. (the “Company”) of her decision to retire in 2025 from her position as Chief Medical Officer of the Company.
On July 11, 2023, the Board of Directors (the “Board”) of Neurocrine Biosciences, Inc., a Delaware corporation (“Neurocrine”), upon the recommendation of its Nominating / Corporate Governance Committee, appointed Christine A. Poon as a member of the Board, effective immediately.
Max materiality 0.95 · Median 0.75 · Most common event earnings